Compare FIGR & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FIGR | BLCO |
|---|---|---|
| Founded | 2018 | 1853 |
| Country | United States | Canada |
| Employees | 602 | N/A |
| Industry | Finance: Consumer Services | Ophthalmic Goods |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 5.9B |
| IPO Year | N/A | 2022 |
| Metric | FIGR | BLCO |
|---|---|---|
| Price | $40.50 | $16.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $53.22 | $18.45 |
| AVG Volume (30 Days) | ★ 3.7M | 479.1K |
| Earning Date | 05-11-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,101,000,000.00 |
| Revenue This Year | $69.23 | $8.65 |
| Revenue Next Year | $24.25 | $5.59 |
| P/E Ratio | $134.36 | ★ N/A |
| Revenue Growth | N/A | ★ 6.47 |
| 52 Week Low | $25.01 | $10.99 |
| 52 Week High | $78.00 | $18.92 |
| Indicator | FIGR | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 59.75 | 48.97 |
| Support Level | $40.30 | $15.36 |
| Resistance Level | $42.98 | $16.61 |
| Average True Range (ATR) | 3.01 | 0.48 |
| MACD | 0.58 | 0.04 |
| Stochastic Oscillator | 67.34 | 73.91 |
Figure Technology Solutions Inc is building the future of capital markets with blockchain technology. proprietary technology powers next-generation lending, trading, and investing activities in areas such as consumer credit and digital assets. Its use of the blockchain ledger allows them to serve their end customers, improve speed and efficiency, and enhance standardization and liquidity. The Company operates as a single operating and reportable segment. The company's geographical operations is within the USA, with the majority of revenue from California.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.